Comparison between Influx Healthtech IPO and Mahamaya Lifesciences IPO.
Influx Healthtech IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Mahamaya Lifesciences IPO is a SME Bookbuilding proposed to list at BSE SME.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Rarever Financial Advisors Pvt.Ltd. | Oneview Corporate Advisors Pvt.Ltd. |
| Registrar | Maashitla Securities Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | R.K.Stock Holding Pvt.Ltd. | Mansi Share & Stock Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | Anchor Investor |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Influx Healthtech IPO is up to ₹55.63 Cr whereas the issue size of the Mahamaya Lifesciences IPO is up to ₹66.91 Cr. The final issue price of Influx Healthtech IPO is ₹96.00 per share and of Mahamaya Lifesciences IPO is ₹114.00 per share.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹91.00 per share | ₹108.00 per share |
| Issue Price (Upper) | ₹96.00 per share | ₹114.00 per share |
| Issue Price (Final) | ₹96.00 per share | ₹114.00 per share |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 1200 shares | 1200 shares |
| Fresh Issue Size | 46,94,400 shares | 53,29,200 shares |
| Fresh Issue Size (Amount) | up to ₹45.07 Cr | up to ₹60.75 Cr |
| OFS Issue Size | 11,00,400 shares | 5,40,000 shares |
| OFS Issue Size (Amount) | up to ₹10.56 Cr | up to ₹6.16 Cr |
| Issue Size Total | 57,94,800 shares | 58,69,200 shares |
| Issue Size Total (Amount) | up to ₹55.63 Cr | up to ₹66.91 Cr |
Influx Healthtech IPO opens on Jun 18, 2025, while Mahamaya Lifesciences IPO opens on Nov 11, 2025. The closing date of Influx Healthtech IPO and Mahamaya Lifesciences IPO is Jun 20, 2025, and Nov 13, 2025, respectively.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Anchor Bid Date | Jun 17, 2025 | Nov 10, 2025 |
| Issue Open | Jun 18, 2025 | Nov 11, 2025 |
| Issue Close | Jun 20, 2025 | Nov 13, 2025 |
| Basis Of Allotment (Tentative) | Jun 23, 2025 | Nov 14, 2025 |
| Initiation of Refunds (Tentative) | Jun 24, 2025 | Nov 17, 2025 |
| Credit of Share (Tentative) | Jun 24, 2025 | Nov 17, 2025 |
| Listing date (Tentative) | Jun 25, 2025 | Nov 18, 2025 |
| Anchor Lockin End date 1 | Jul 23, 2025 | Dec 13, 2025 |
| Anchor Lockin End date 2 | Sep 21, 2025 | Feb 11, 2026 |
Influx Healthtech IPO P/E ratio is 13.04, as compared to Mahamaya Lifesciences IPO P/E ratio of 15.65.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Influx Healthtech Ltd.'s revenue increased by 5% and profit after tax (PAT) rose by 19% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Mahamaya Lifesciences Ltd.'s revenue increased by 64% and profit after tax (PAT) rose by 148% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.85 | 77.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.53 | 56.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 13.04 | 15.65 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹222.24 Cr. | ₹266.82 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 36.98% | 34.94% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 49.17% | 23.15% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.01 | 1.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.36 | ₹7.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 36.98% | 26.19% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Influx Healthtech IPO Retail Individual Investors (RII) are offered 20,29,200 shares while in Mahamaya Lifesciences IPO retail investors are offered 20,29,200 shares. Qualified Institutional Buyers (QIB) are offered 11,59,200 shares in Influx Healthtech IPO and 11,76,000 shares in Mahamaya Lifesciences IPO.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,36,400 shares | 17,52,000 shares |
| Market Maker Reservation | 3,06,000 shares | 3,09,600 shares |
| QIB | 11,59,200 shares | 11,76,000 shares |
| NII | 8,70,000 shares | 8,82,000 shares |
| RII | 20,29,200 shares | 20,59,200 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 57,94,800 shares | 58,69,200 shares |
Influx Healthtech IPO subscribed 201.35x in total, whereas Mahamaya Lifesciences IPO subscribed 1.63x.
| Influx Healthtech IPO | Mahamaya Lifesciences IPO | |
|---|---|---|
| QIB (times) | 137.87x | 1.19x |
| NII (times) | 481.10x | 3.63x |
| Big NII (times) | 5.00x | |
| Small NII (times) | 0.90x | |
| RII (times) | 117.68x | 1.02x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 201.35x | 1.63x |
